A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Phase 1 Completed
99 enrolled 11 charts
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1 Completed
50 enrolled
HAITILS
Phase 1 Completed
8 enrolled
Haplo Peripheral Blood Sct In GVHD Prevention
Phase 1 Completed
25 enrolled
IAC
Phase 1 Completed
5 enrolled
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Phase 1 Completed
240 enrolled 2 FDA
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase 1 Completed
25 enrolled
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
Phase 1 Completed
25 enrolled
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Completed
29 enrolled
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
Phase 1 Completed
20 enrolled
Chemotherapy in Treating Children With Neuroblastoma
Phase 1 Completed
BMT-03
Phase 1 Completed
12 enrolled 12 charts
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Phase 1 Completed
150 enrolled 9 charts
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma
Phase 1 Completed
34 enrolled
BSO
Phase 1 Completed
31 enrolled
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
14 enrolled
HaploOnly
Phase 1 Completed
74 enrolled
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Phase 1 Completed
11 enrolled
SIAC
Phase 1 Completed
12 enrolled
Cord Blood Expansion on Mesenchymal Stem Cells
Phase 1 Completed
98 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 1 Completed
131 enrolled
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 1 Completed
20 enrolled
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
Phase 1 Completed
3 enrolled
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1 Completed
11 enrolled
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Completed
30 enrolled
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
Phase 1 Completed
8 enrolled
Ewing/Allo
Phase 1 Completed
10 enrolled
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1 Completed
33 enrolled
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Phase 1 Completed
22 enrolled
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
Phase 1 Completed
34 enrolled
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 1 Completed
20 enrolled
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase 1 Completed
145 enrolled
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Phase 1 Completed
78 enrolled
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
Phase 1 Completed
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
Phase 1 Completed
15 enrolled
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
Phase 1 Completed
20 enrolled
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1 Completed
8 enrolled
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Completed
35 enrolled
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Phase 1 Completed
38 enrolled
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
Phase 1 Completed
31 enrolled
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Completed
101 enrolled 15 charts
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
Phase 1 Completed
12 enrolled
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
10 enrolled
Melphalan in Patients With Neoplastic Meningitis
Phase 1 Completed
6 enrolled
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Completed
44 enrolled
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Phase 1 Completed
10 enrolled